Omnicell (NASDAQ:OMCL) Earns “Buy” Rating from Benchmark

Benchmark reaffirmed their buy rating on shares of Omnicell (NASDAQ:OMCL) in a research report report published on Wednesday morning, Benzinga reports. Benchmark currently has a $48.00 target price on the stock.

A number of other brokerages also recently weighed in on OMCL. JPMorgan Chase & Co. raised their target price on shares of Omnicell from $26.00 to $37.00 and gave the company a neutral rating in a research note on Friday, August 23rd. Wells Fargo & Company raised their target price on shares of Omnicell from $26.00 to $30.00 and gave the company an equal weight rating in a research note on Friday, August 2nd. Bank of America raised their target price on shares of Omnicell from $34.00 to $44.00 and gave the company a buy rating in a research note on Friday, August 2nd. StockNews.com downgraded shares of Omnicell from a buy rating to a hold rating in a research note on Thursday, September 19th. Finally, Barclays raised shares of Omnicell from an underweight rating to an equal weight rating and lifted their price target for the stock from $26.00 to $39.00 in a research note on Friday, August 2nd. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $39.50.

Omnicell Price Performance

Shares of NASDAQ:OMCL opened at $42.62 on Wednesday. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $1.96 billion, a PE ratio of -92.65, a P/E/G ratio of 47.35 and a beta of 0.83. Omnicell has a twelve month low of $25.12 and a twelve month high of $45.84. The company has a 50-day moving average price of $43.04 and a two-hundred day moving average price of $33.82.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The company had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. During the same period last year, the business earned $0.29 earnings per share. Omnicell’s revenue was down 7.4% compared to the same quarter last year. Equities analysts forecast that Omnicell will post 0.64 EPS for the current year.

Institutional Trading of Omnicell

Several large investors have recently added to or reduced their stakes in the stock. Nebula Research & Development LLC bought a new stake in shares of Omnicell during the 4th quarter valued at $891,000. Caxton Associates LP bought a new stake in shares of Omnicell during the 4th quarter valued at $2,115,000. Greenwood Capital Associates LLC boosted its holdings in shares of Omnicell by 12.9% during the 4th quarter. Greenwood Capital Associates LLC now owns 12,659 shares of the company’s stock valued at $476,000 after buying an additional 1,447 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Omnicell by 8.5% during the 4th quarter. Vanguard Group Inc. now owns 5,571,420 shares of the company’s stock valued at $209,653,000 after buying an additional 434,336 shares in the last quarter. Finally, Counterpoint Mutual Funds LLC bought a new stake in shares of Omnicell during the 1st quarter valued at $300,000. Institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.